Annual SG&A
$54.28 M
+$23.68 M+77.41%
30 April 2024
Summary:
KalVista Pharmaceuticals annual selling, general & administrative expenses is currently $54.28 million, with the most recent change of +$23.68 million (+77.41%) on 30 April 2024. During the last 3 years, it has risen by +$37.64 million (+226.25%). KALV annual SG&A is now at all-time high.KALV Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$17.60 M
-$5.61 M-24.16%
31 July 2024
Summary:
KalVista Pharmaceuticals quarterly selling, general & administrative expenses is currently $17.60 million, with the most recent change of -$5.61 million (-24.16%) on 31 July 2024. Over the past year, it has increased by +$6.94 million (+65.16%). KALV quarterly SG&A is now -24.16% below its all-time high of $23.21 million, reached on 30 April 2024.KALV Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.80 B
-$141.77 M-8.54%
31 July 2024
Summary:
KalVista Pharmaceuticals TTM selling, general & administrative expenses is currently -$1.80 billion, with the most recent change of -$141.77 million (-8.54%) on 31 July 2024. Over the past year, it has dropped by -$1.84 billion (-5230.82%). KALV TTM SG&A is now -5133.09% below its all-time high of $62.09 million, reached on 31 July 2024.KALV TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KALV Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +77.4% | +65.2% | -5230.8% |
| 3 y3 years | +226.3% | +190.6% | -8426.9% |
| 5 y5 years | +396.8% | +414.6% | -10000.0% |
KALV Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +226.3% | -24.2% | +190.6% | -154.3% | at low |
| 5 y | 5 years | at high | +396.8% | -24.2% | +473.7% | -371.5% | at low |
| alltime | all time | at high | +3771.5% | -24.2% | +4682.9% | -5133.1% | at low |
KalVista Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| July 2024 | - | $17.60 M(-24.2%) | $62.09 M(+14.4%) |
| Apr 2024 | $54.28 M(+77.4%) | $23.21 M(+118.4%) | $54.28 M(+39.7%) |
| Jan 2024 | - | $10.63 M(-0.3%) | $38.85 M(+10.7%) |
| Oct 2023 | - | $10.66 M(+8.9%) | $35.10 M(+8.8%) |
| July 2023 | - | $9.79 M(+25.8%) | $32.25 M(+5.4%) |
| Apr 2023 | $30.59 M(+15.7%) | $7.78 M(+13.0%) | $30.59 M(+0.6%) |
| Jan 2023 | - | $6.88 M(-11.8%) | $30.42 M(-0.2%) |
| Oct 2022 | - | $7.81 M(-4.0%) | $30.48 M(+6.1%) |
| July 2022 | - | $8.13 M(+7.0%) | $28.73 M(+8.6%) |
| Apr 2022 | - | $7.60 M(+9.4%) | $26.45 M(+5.7%) |
| Apr 2022 | $26.45 M(+59.0%) | - | - |
| Jan 2022 | - | $6.95 M(+14.7%) | $25.01 M(+15.7%) |
| Oct 2021 | - | $6.06 M(+3.6%) | $21.63 M(+12.6%) |
| July 2021 | - | $5.85 M(-5.2%) | $19.20 M(+15.4%) |
| Apr 2021 | $16.64 M(+27.7%) | $6.17 M(+73.2%) | $16.64 M(+20.8%) |
| Jan 2021 | - | $3.56 M(-2.0%) | $13.77 M(+3.7%) |
| Oct 2020 | - | $3.63 M(+10.8%) | $13.28 M(+1.6%) |
| July 2020 | - | $3.28 M(-0.5%) | $13.06 M(+0.2%) |
| Apr 2020 | $13.03 M(+19.2%) | $3.30 M(+7.4%) | $13.03 M(+1.9%) |
| Jan 2020 | - | $3.07 M(-10.3%) | $12.78 M(+1.3%) |
| Oct 2019 | - | $3.42 M(+5.3%) | $12.61 M(+6.9%) |
| July 2019 | - | $3.25 M(+6.6%) | $11.80 M(+8.0%) |
| Apr 2019 | $10.93 M | $3.05 M(+5.1%) | $10.93 M(+11.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2019 | - | $2.90 M(+11.2%) | $9.84 M(+8.5%) |
| Oct 2018 | - | $2.61 M(+10.0%) | $9.07 M(-1.0%) |
| July 2018 | - | $2.37 M(+21.2%) | $9.16 M(+3.4%) |
| Apr 2018 | $8.86 M(-20.7%) | $1.96 M(-8.1%) | $8.86 M(-2.7%) |
| Jan 2018 | - | $2.13 M(-21.2%) | $9.11 M(-24.1%) |
| Oct 2017 | - | $2.70 M(+30.4%) | $12.01 M(+5.5%) |
| July 2017 | - | $2.07 M(-5.9%) | $11.38 M(-4.5%) |
| Apr 2017 | $11.18 M(+321.3%) | $2.20 M(-56.1%) | $11.91 M(+5.9%) |
| Jan 2017 | - | $5.03 M(+141.6%) | $11.25 M(+49.2%) |
| Sept 2016 | - | $2.08 M(-20.1%) | $7.54 M(+10.3%) |
| June 2016 | - | $2.60 M(+68.8%) | $6.84 M(+26.5%) |
| Apr 2016 | $2.65 M(-45.5%) | - | - |
| Mar 2016 | - | $1.54 M(+17.2%) | $5.40 M(+11.0%) |
| Dec 2015 | $4.87 M(+202.6%) | $1.32 M(-4.1%) | $4.87 M(+12.0%) |
| Sept 2015 | - | $1.37 M(+17.4%) | $4.34 M(-2.6%) |
| June 2015 | - | $1.17 M(+16.3%) | $4.46 M(+12.0%) |
| Apr 2015 | $1.61 M(-52.9%) | - | - |
| Mar 2015 | - | $1.01 M(+26.7%) | $3.98 M(+16.7%) |
| Dec 2014 | $3.41 M(+143.4%) | $794.00 K(-46.7%) | $3.41 M(+14.3%) |
| Sept 2014 | - | $1.49 M(+115.6%) | $2.99 M(+99.6%) |
| June 2014 | - | $691.00 K(+58.1%) | $1.50 M(+85.8%) |
| Mar 2014 | - | $437.00 K(+18.8%) | $805.00 K(+118.8%) |
| Dec 2013 | $1.40 M(-0.7%) | $368.00 K | $368.00 K |
| Dec 2012 | $1.41 M | - | - |
FAQ
- What is KalVista Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals annual SG&A year-on-year change?
- What is KalVista Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals quarterly SG&A year-on-year change?
- What is KalVista Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals TTM SG&A year-on-year change?
What is KalVista Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of KALV is $54.28 M
What is the all time high annual SG&A for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high annual selling, general & administrative expenses is $54.28 M
What is KalVista Pharmaceuticals annual SG&A year-on-year change?
Over the past year, KALV annual selling, general & administrative expenses has changed by +$23.68 M (+77.41%)
What is KalVista Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of KALV is $17.60 M
What is the all time high quarterly SG&A for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $23.21 M
What is KalVista Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, KALV quarterly selling, general & administrative expenses has changed by +$6.94 M (+65.16%)
What is KalVista Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of KALV is -$1.80 B
What is the all time high TTM SG&A for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high TTM selling, general & administrative expenses is $62.09 M
What is KalVista Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, KALV TTM selling, general & administrative expenses has changed by -$1.84 B (-5230.82%)